Skip to main content
TipRanks
Go Ultimate75% OFF

Alexium International Group (AJX) AI Stock Analysis

7 Followers
AU:AJX

Alexium International Group

(ASX:AJX)

Select Model
Rating:37Underperform
Price Target:AUD 0.01â–²(80.00% Upside)
Action:reiterated
Date:09/06/26

The overall score is at the absolute minimum, reflecting a company in severe financial distress. The most significant factor is the insolvent balance sheet and deeply negative cash flows, which pose an existential threat. This is compounded by a complete lack of positive technical or valuation signals, with the stock trading as a penny share with no momentum data available.

Positive Factors
FY2026 Revenue ReboundThe FY2026 revenue rebound indicates renewed commercial activity across Alexium’s specialty materials business after several years of declines. If customer adoption and processed-material volumes remain elevated, the improved top line could provide a base for operating leverage over the next several quarters.
Negative Factors
Widening Losses and Margin PressureThe revenue rebound has not translated into stronger earnings power: gross margin contracted materially and net losses widened. Persistent negative margins weaken internal funding capacity and suggest that additional revenue growth may not produce durable profitability without better cost absorption or pricing.

Alexium International Group (AJX) vs. iShares MSCI Australia ETF (EWA)

Not enough price history over this period.

Market Cap
AUD 19.10M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.4
Beta (1Y)
0.48
Revenue Growth
2.85%
EPS Growth
-13.89%
Country
Australia
Employees
319
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

Alexium International Group Business Overview & Revenue Model

Company Description

Alexium International Group Limited is a U.S.-based firm specializing in the production and distribution of phase-change materials (PCM) and various advanced textile technologies. The company's portfolio includes a range of thermal management solutio...

How the Company Makes Money

Alexium makes money primarily by selling its specialty chemistries and treatment solutions and by providing related application/processing services for customers who apply these technologies to fabrics or other substrates. Key revenue streams typical...

Alexium International Group Financial Statement Overview

Summary

Financial health is critically poor. The income statement shows widening losses and collapsing margins despite a 107% revenue surge. The balance sheet is technically insolvent with negative equity, and operating cash flow is deeply negative, indicating a severe cash burn and existential liquidity risk.

Income Statement

18Very Negative

Balance Sheet

8Very Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue4.23M4.24M3.92M5.89M7.19M8.14M
Gross Profit1.23M1.23M1.69M2.64M2.81M3.32M
EBITDA-4.17M-4.23M―-931.08K-1.37M-1.54M
Net Income-2.13M-6.29M-3.93M-2.76M-2.95M-3.36M
Balance Sheet
Total Assets2.33M2.34M2.88M5.23M5.37M6.40M
Cash, Cash Equivalents and Short-Term Investments216.99K217.24K662.45K2.05M511.78K1.02M
Total Debt1.32M1.32M2.55M969.43K4.69M3.85M
Total Liabilities2.68M2.68M3.28M1.93M6.35M4.83M
Stockholders Equity-343.08K-343.49K-402.08K3.30M-980.26K1.57M
Cash Flow
Free Cash Flow-3.15M-3.21M-2.80M-1.35M-1.49M-1.93M
Operating Cash Flow-3.15M-3.20M-2.58M-1.19M-1.10M-1.57M
Investing Cash Flow-6,966-7,845-218.09K-156.22K-385.41K-353.35K
Financing Cash Flow2.70M2.79M1.42M2.91M992.85K74.01K

Alexium International Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

AU:AJX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
AU:CG1AU:CG144NeutralAUD 23.40M-4.95-75.44%―-3.10%39.78%
AU:TTTAU:TTT43NeutralAUD 146.77M-3.42-74.68%―-1.41%-4.04%
AU:DTZAU:DTZ40UnderperformAUD 8.64M-0.52268.53%―-74.92%-46.21%
AU:SPNAU:SPN40UnderperformAUD 18.61M-6.25-113.85%――-0.43%
AU:AJXAU:AJX37UnderperformAUD 19.10M-1.44458.56%―2.85%-13.89%
AU:CXLAU:CXL37UnderperformAUD 52.98M-1.02-119.47%―27.85%-141.00%

* Basic Materials Sector Average

Performance Comparison

0%100%AU:TTTAU:DTZAU:SPNAU:CXLAU:CG1Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:AJX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:AJXAlexium International Group Limited―――
AU:TTTTitomic Ltd0.08-0.13-61.43%
AU:DTZDotz Nano Limited0.01-0.04-76.60%
AU:SPNSparc Technologies Ltd0.14-0.01-3.33%
AU:CXLCalix Ltd.0.24-0.32-57.02%
AU:CG1Carbonxt Group Ltd.0.05-0.04-43.16%

Alexium International Group Corporate Events

Alexium Files Updated Corporate Governance Statement With ASX

Aug 28, 2026

Alexium International Group Limited has lodged its corporate governance statement for the year ended 30 June 2026 with the ASX, confirming that the document is current as of 28 August 2026 and accessible via its investor relations website. The filing...

Alexium Releases 2026 Annual Report and Sets Investor Webinar

Aug 28, 2026

Alexium International Group Limited, a specialist provider of performance chemicals for advanced materials, focuses on flame retardancy and thermal management solutions across bedding, body armour, military uniforms and workwear. Its patent-protected...

Alexium Issues 4Q26 Results Briefing With Extensive Investor Disclaimers

Jul 31, 2026

Alexium International Group Limited, a specialty chemicals and advanced materials provider, reports its financial results in U.S. dollars to align with its operating and investor base. The company’s governance and disclosure practices follow Australi...

Alexium Navigates Q4 Production Setback as mPCM and Flame-Resistant Coatings Strategy Advances

Jul 31, 2026

Alexium International Group reported a challenging fourth quarter of FY26 as manufacturing problems at its Dayton facility disrupted production and delayed an anticipated sales ramp-up following the Microtek Laboratories acquisition. While technology...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026